Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldstein

Showing results (391-400 of 518) with videos related to

Pageof 52
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimatesBelinda E Kiely, Andrew J Martin, Martin H N Tattersall, et al.
Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.
BMC Cancer|April 25, 2018
The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancerMegan Best, Ainsley J Newson, Bettina Meiser, et al.
BMC Cancer|April 7, 2018
The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profilingMegan Best, Ainsley J Newson, Bettina Meiser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Oral Oncology|July 18, 2016
A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancerSjoukje F Oosting, Tom W W Chen, Shao H Huang, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 15, 2022
Prognostic models to predict survival in patients with pancreatic cancer: a systematic reviewLiane J Ioannou, Ashika D Maharaj, John R Zalcberg, et al.
Cancer Epidemiology|November 5, 2013
The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer CentreSteven Habbous, Karen P Chu, Xin Qiu, et al.
Oral Oncology|October 20, 2012
Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failureAndrew K Chan, Shao Hui Huang, Lisa W Le, et al.
Pageof 52

Showing results (391-400 of 518) with videos related to

Sort By:
Pageof 52
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimatesBelinda E Kiely, Andrew J Martin, Martin H N Tattersall, et al.
Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.
BMC Cancer|April 25, 2018
The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancerMegan Best, Ainsley J Newson, Bettina Meiser, et al.
BMC Cancer|April 7, 2018
The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profilingMegan Best, Ainsley J Newson, Bettina Meiser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Oral Oncology|July 18, 2016
A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancerSjoukje F Oosting, Tom W W Chen, Shao H Huang, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 15, 2022
Prognostic models to predict survival in patients with pancreatic cancer: a systematic reviewLiane J Ioannou, Ashika D Maharaj, John R Zalcberg, et al.
Cancer Epidemiology|November 5, 2013
The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer CentreSteven Habbous, Karen P Chu, Xin Qiu, et al.
Oral Oncology|October 20, 2012
Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failureAndrew K Chan, Shao Hui Huang, Lisa W Le, et al.
Pageof 52